Evaluation of cytogenetic response in CML patients with variant Philadelphia translocation. Issue 1 (25th February 2021)

• Record Type: Journal Article
• Authors: Shetty, Dhanlaxmi; Talker, Elizabeth; Jain, Hemani; Talker, Judith; Patkar, Nikhil; Subramanian, Papagudi; Jain, Hasmukh; Bonda, Avinash; Punatar, Sachin; Gokarn, Anant; Bagal, Bhausaheb; Sengar, Manju; Khattry, Navin
• Is Part Of: Asia-Pacific journal of clinical oncology. Volume 18:Issue 1(2022)
• Page Start: 99
• Page End: 108
• Publication Date: 2021-02-25
• Subjects: tyrosine kinase domain mutation -- variant chronic myeloid leukaemia; Oncology -- Pacific Area -- Periodicals; Cancer -- Treatment -- Pacific Area -- Periodicals; Cancer -- Pacific Area -- Periodicals; Cancer -- Treatment -- Periodicals; 616.9940095
• DOI: 10.1111/ajco.13522
• Languages: English
• ISSNs: 1743-7555

Abstract

Abstract: Background and aim: Molecular mechanism of translocation and outcome in variant chronic myeloid leukaemia (vCML) has been a topic of debate. While several cytogenetic studies suggest a low response to Imatinib Mesylate, others demonstrate a similar disease course in both classical and vCML. Besides, many studies comprehensively also link tyrosine kinase domain (TKD) mutations with aggressive clinical outcome. Thus, we aim to study the molecular mechanism of translocation, identify the third partner chromosomes and comment on the disease course and clinical outcome. Method: We cytogenetically characterised 25 vCML cases to determine the third partner chromosome, mechanism of translocation and prognostic outcome. We also compared vCML cases with and without TKD mutation to most appropriately outline the clinical consequence and ascertain the potent cause of unresponsiveness to treatment. Results: Third partner chromosome in variant translocation was defined by conventional and molecular cytogenetics. Although in our study most cases showed inadequate clinical response attributable to TKD mutation rather than variant translocation, we observed an inferior outcome in cases involving chromosome 5 as the third partner. Conclusion: Thus, we conclude that characterising and reporting new cases of variant translocations, involving various different chromosomes as third partner (with different breakpoints) by cytogenetics, will lead to a better understanding of the disease. To the best of our knowledge, this kind of delineate study has not been applied to precisely comment on the prospects of cytogenetically characterised vCML. Abstract : The study about variant translocation is still unclear in terms of prognosis, response to treatment and overall survival. Characterisation of vCML patients by metaphase fluorescence in situ hybridisation to determine possible genes involved in pathogenesis will add to the data pool and help summarise the current knowledge about variant CML.